Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 5/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338423 | 0.88 | HRH2 (0.46) | HRH2HRH1MMP2MMP3BACE1 | |
| SCHEMBL12607429 | 0.84 | FYN (0.42) | — | |
| SCHEMBL12607437 | 0.84 | CYP1A2 (0.39) | HRH3 | |
| SCHEMBL12607431 | 0.83 | KIF11 (0.40) | GPR119 | |
| SCHEMBL1785777 | 0.82 | GPR119 (0.40) | BACE1GPR119 | |
| SCHEMBL12607465 | 0.81 | MAPT (0.41) | GPR119 | |
| SCHEMBL1786986 | 0.80 | LSS (0.43) | GPR119 | |
| SCHEMBL1788288 | 0.80 | ALDH1A1 (0.41) | MCHR1HRH3 | |
| SCHEMBL12651138 | 0.80 | CPT2 (0.39) | GPR119 | |
| SCHEMBL12607436 | 0.79 | CYP1A2 (0.45) | HRH3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HRH2 416/4885HRH1 437/4885MMP2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.